BMN-673: Phase III ongoing

Myriad Genetics Inc. (NASDAQ:MYGN, Salt Lake City, Utah) said BioMarin will use Myriad's BRACAnalysis in BioMarin's ongoing, open-label Phase III trial comparing 1 mg oral BMN 673 once daily vs. physician's choice of capecitabine, gemcitabine, eribulin or vinorelbine in 430 metastatic breast cancer patients with BRCA mutations. Myriad Genetics has submitted an investigational device exemption (IDE) to FDA to use the test as a companion diagnostic to stratify patients in the BMN 673 clinical program. Myriad Genetics markets BRACAnalysis to assess a woman's risk of developing breast or ovarian cancer based on detecting genetic mutations in the BRCA1 and BRCA2 genes. ...